Exact Sciences launches Oncodetect for Molecular Residual Disease (MRD) Detection
Shots:
- Exact Sciences has launched Oncodetect to detect MRD across multiple solid tumors, with its efficacy supported by strong clinical validation, incl. ~5yrs. of follow-up data from the Alpha-CORRECT study
- Addiitonally, clinical & analytical validation studies across multiple solid tumors are underway, supported by strategic partnerships for multi-cancer evidence generation
- Oncodetect test provides clear “Detected” or “Not Detected” results with quantitative data to guide adjuvant therapy, assess treatment response, & monitor recurrence while tracking ~200 tumor-specific variants to detect 1 ctDNA molecule in 20,000 cfDNA molecules
Ref: Businesswire | Image: Exact Sciences
Related News:- Exact Sciences Reports the US FDA’s Approval of Cologuard Plus Test for Non-Invasive Colorectal Cancer Screening
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
